ipharmacenter Consulting services

The European Commission has granted conditional marketing authorisation for Sanofi’s Rezurock (belumosudil) to treat chronic graft-versus-host disease (GVHD) in adults and adolescents aged 12 years and older who weigh at least 40 kg. The approval offers a critical treatment option for patients who have limited benefit from current therapies or have exhausted existing options. Also read: Top 10 Pharmaceutical Companies by Revenue 2025 The decision is supported by evidence from

Bimzelx (bimekizumab) showed marked superiority over Skyrizi (risankizumab) in improving symptoms of active psoriatic arthritis, achieving statistically significant results at Week 16 as measured by the ACR50 response. This marks the first time a licensed biologic therapy has shown clear superiority over an IL-23 inhibitor in psoriatic arthritis. BE BOLD represents the fourth head-to-head study within the Bimzelx clinical program to demonstrate superior outcomes in psoriatic